Review
Nature Reviews Cancer 4, 457-469 (June 2004) | doi:10.1038/nrc1368
The potential of positron-emission tomography to study anticancer-drug resistance
Catharine M. L West1, Terry Jones1 & Pat Price1 About the authors
Abstract
Positron-emission tomography (PET) is a powerful tool for imaging and quantifying cellular and molecular processes in humans. It has enormous potential to increase our understanding of the pathophysiology of human tumours and to support the development of anticancer drugs. The ability of PET to image mechanisms of anticancer-drug resistance in vivo should be exploited in proof-of-concept studies at early stages of drug development.
- View At a Glance
Author affiliations
- Academic Department of Radiation Oncology and Manchester Molecular Imaging Centre, University of Manchester, Christie NHS Trust Hospital, Wilmslow Road, Manchester, M20 4BX, United Kingdom.
Correspondence to: Catharine M. L West1 Email: west@man.ac.uk
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasionOncogene Original Article
[ 18 F]FDG and [ 18 F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro studyBritish Journal of Cancer Original Article
Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomographyCancer Gene Therapy Original Article
See all 15 matches for Research